Please note that this product was withdrawn from the Community Register of designated Orphan Medicinal Products in July 2018 on request of the Sponsor.

On 1 October 2010, orphan designation (EU/3/10/796) was granted by the European Commission to XOMA Ireland Ltd, Ireland, for recombinant humanised anti-human interleukin-1 beta monoclonal antibody for the treatment of Behçet's disease.

The sponsorship was transferred to Les Laboratoires Servier, France, in December 2011 and subsequently to XOMA UK Limited, United Kingdom, in February 2016.

Key facts

Active substance
Recombinant humanised anti-human interleukin-1 beta monoclonal antibody
Disease / condition
Treatment of Behçet's Disease
Date of decision
Orphan decision number

Review of designation

The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.

Sponsor's contact details

XOMA UK Limited
c/o Arnold & Porter (UK) LLP
Tower 42
25 Old Broad Street
London EC2N 1HQ
United Kingdom
Tel. +44 (0)20 7786 6104

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;
  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

How useful was this page?

Add your rating